Zacks: Analysts Anticipate Dyne Therapeutics, Inc. (NYSE:DYN) Will Post Earnings of -$0.81 Per Share

Brokerages expect Dyne Therapeutics, Inc. (NYSE:DYNGet Rating) to report earnings per share (EPS) of ($0.81) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Dyne Therapeutics’ earnings. The lowest EPS estimate is ($0.88) and the highest is ($0.70). Dyne Therapeutics reported earnings per share of ($0.58) in the same quarter last year, which indicates a negative year-over-year growth rate of 39.7%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Dyne Therapeutics will report full-year earnings of ($3.36) per share for the current financial year, with EPS estimates ranging from ($3.64) to ($2.86). For the next fiscal year, analysts expect that the company will report earnings of ($3.71) per share, with EPS estimates ranging from ($4.70) to ($2.67). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Dyne Therapeutics.

Dyne Therapeutics (NYSE:DYNGet Rating) last announced its quarterly earnings results on Monday, May 2nd. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.19.

Separately, StockNews.com began coverage on shares of Dyne Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company.

Shares of DYN opened at $4.58 on Thursday. The company has a fifty day moving average of $7.39. Dyne Therapeutics has a 1-year low of $4.30 and a 1-year high of $22.92.

Dyne Therapeutics Company Profile (Get Rating)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Further Reading

Get a free copy of the Zacks research report on Dyne Therapeutics (DYN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.